A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD

References

• PriceD, ChisholmA, RyanD, CrockettA, JonesR. The use of roflumilast in COPD: a primary care perspective. Primary Care Respiratory j. 2010;19(4):342–351. doi:10.4104/pcrj.2010.00066
   PubMedGoogle Scholar
• Chronic obstructive pulmonary disease (COPD) statistics. Available from: https://statistics.blf.org.uk/copd. Accessed 3 2018.
   Google Scholar
• Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Available from: https://www.nice.org.uk/guidance/cg101. Accessed 3 2018.
   Google Scholar
• Stockton-on-tees Borough Council. Joint Strategic Needs Assessment. 2009.
   Google Scholar
• PriceD, YawnB, BrusselleG, RossiA. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Primary Care Respiratory j. 2013;22(1):92–100. doi:10.4104/pcrj.2012.00092
   PubMedGoogle Scholar
• PriceD, WestD, BrusselleG, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904. doi:10.2147/COPD.S6275025210450
   PubMed Web of Science ®Google Scholar
• NanniniLJ, PooleP, MilanSJ, KestertonA. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Systematic Reviews. 2013;8:Cd006826.
   PubMed Web of Science ®Google Scholar
• EMC. Fostair 100/6 inhalation solution. Available from: https://www.medicines.org.uk/emc/product/6318/smpc. Accessed 315, 2018.
   Google Scholar
• ScichiloneN, BattagliaS, SorinoC, et al. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy. 2010;65(7):897–902. doi:10.1111/j.1398-9995.2009.02306.x20121764
   PubMed Web of Science ®Google Scholar
• ScichiloneN, BenfanteA, MorandiL, BelliniF, PapiA. Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD. Patient Relat Outcome Meas. 2014;5:153–162.25473323
   PubMedGoogle Scholar
• CalverleyPM, KunaP, MonsoE, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010;104(12):1858–1868. doi:10.1016/j.rmed.2010.09.00820965712
   PubMed Web of Science ®Google Scholar
• VehringR, Lechuga-BallesterosD, JoshiV, NogaB, DwivediSK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. ACS j Surfaces Colloids. 2012;28(42):15015–15023. doi:10.1021/la302281n
   Web of Science ®Google Scholar
• SinghD, NicoliniG, BindiE, et al. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulm Med. 2014;14:43. doi:10.1186/1471-2466-14-4324621109
   PubMed Web of Science ®Google Scholar
• PriceD, SmallI, HaughneyJ, et al. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Primary Care Respiratory j. 2013;22(4):439–448. doi:10.4104/pcrj.2013.00088
   PubMedGoogle Scholar
• OPCRD. The Optimum Patient Care Research Database (OPCRD). Available from: https://opcrd.co.uk/. Accessed 6 2018.
   Google Scholar
• EMC. Fostair 100/6 inhalation solution. Available from: https://www.medicines.org.uk/emc/medicine/21006/SPC/Fostair+100+6+inhalation+solution/. Accessed 1 2016.
   Google Scholar
• EMC. Seretide 100, 250, 500 accuhaler. Available from: https://www.medicines.org.uk/emc/medicine/2317. Accessed 1 2016.
   Google Scholar
• EMC. Symbicort turbohaler 200/6 inhalation powder. Available from: https://www.medicines.org.uk/emc/medicine/4821. Accessed 1 2016.
   Google Scholar
• EMC. Symbicort turbohaler 400/12, inhalation powder. Available from: https://www.medicines.org.uk/emc/medicine/11882. Accessed 1 2016.
   Google Scholar
• HagedornC, KassnerF, BanikN, NtampakasP, FielderK. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD. Respir Med. 2013;107(4):542–549. doi:10.1016/j.rmed.2012.12.02023337300
   PubMed Web of Science ®Google Scholar
• MagnussenH, DisseB, Rodriguez-RoisinR, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa140715425196117
   PubMed Web of Science ®Google Scholar
• WedzichaJA, SinghD, VestboJ, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108(8):1153–1162. doi:10.1016/j.rmed.2014.05.01324953015
   PubMed Web of Science ®Google Scholar
• SinghD, VezzoliS, PetruzzelliS, PapiA. The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not “frequent exacerbators”: a post hoc analysis of the FORWARD study. Int J Chron Obstruct Pulmon Dis. 2017;12:3263–3271. doi:10.2147/COPD.S14141629138555
   PubMed Web of Science ®Google Scholar
• van der MolenT, PostmaDS, MartinRJ, et al. Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands. BMC Pulm Med. 2016;16(1):80. doi:10.1186/s12890-016-0234-027184175
   PubMed Web of Science ®Google Scholar
• SonnappaS, MartinR, IsraelE, et al. Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS One. 2017;12(6):e0178112. doi:10.1371/journal.pone.017811228617814
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2018 Available from: https://www.nice.org.uk/guidance/ng115. Accessed 225, 2019.
   Google Scholar
• RocheN, ReddelHK, AgustiA, et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respiratory Medicine. 2013;1(10):e29–30.24461762
   PubMed Web of Science ®Google Scholar
• RocheN, ReddelH, MartinR, et al. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc. 2014;11(Suppl 2):S99–104. doi:10.1513/AnnalsATS.201309-300RM24559028
   PubMedGoogle Scholar
• DekhuijzenPNR, BatsiouM, BjermerL, et al. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. Respir Med. 2016;120:54–63. doi:10.1016/j.rmed.2016.09.01527817816
   PubMed Web of Science ®Google Scholar
• CovveyJR, MullenAB, RyanM, et al. A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom. Int J Clin Pract. 2014;68(10):1200–1208. doi:10.1111/ijcp.1245124797899
   PubMed Web of Science ®Google Scholar
• MuellerS, WilkeT, BechtelB, PunekarYS, MitznerK, VirchowJC. Non-persistence and non-adherence to long-acting COPD medication therapy: A retrospective cohort study based on a large German claims dataset. Respir Med. 2017;122:1–11. doi:10.1016/j.rmed.2016.11.00827993284
   PubMed Web of Science ®Google Scholar
• SteinerJF, ProchazkaAV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105–116. doi:10.1016/S0895-4356(96)00268-59048695
   PubMed Web of Science ®Google Scholar
• WrightJ, BrocklebankD, RamF. Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD). Qual Saf Health Care. 2002;11(4):376–382. doi:10.1136/qhc.11.4.37612468702
   PubMedGoogle Scholar
• MelaniAS, BonaviaM, CilentiV, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938. doi:10.1016/j.rmed.2011.01.00521367593
   PubMed Web of Science ®Google Scholar
• MolimardM, RaherisonC, LignotS, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49:2. doi:10.1183/13993003.01794-2016
   Web of Science ®Google Scholar
• HaughneyJ, PriceD, BarnesNC, VirchowJC, RocheN, ChrystynH. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010;104(9):1237–1245. doi:10.1016/j.rmed.2010.04.01220472415
   PubMed Web of Science ®Google Scholar
• MontuschiP, MalerbaM, SantiniG, MiravitllesM. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today. 2014;19(12):1928–1935. doi:10.1016/j.drudis.2014.08.00425182512
   PubMed Web of Science ®Google Scholar